RJH Biosciences is focused on realizing the full potential of gene medicine for human health by developing vehicles to effectively deliver nucleic acids.
We develop novel transfection agents that deliver different types of nucleic acids to a range of human cells in culture, while tailoring the transfection agents further to act as delivery vehicles for preclinical models and clinical therapy involving nucleic acids.
The company was established in 2016 based on the long history of technical expertise developed at the University of Alberta (Edmonton, Alberta, Canada).
The company develops value-added products in three commercial segments, as transfection reagents for biomedical R&D enterprise, as transfection reagents in biomanufacturing industry and as nucleic acid delivery agents for preclinical and clinical applications.
We design and develop unique materials for effective delivery of nucleic acids to meet the emerging needs in biomedical enterprise. Accomplishing the task at hand is what drives our venture.
We are dedicated to understanding the performance of our products in the hands of our customers to reveal the scientific basis of their actions. Establishing such a foundation will guide our efforts to overcome future challanges
Collaboration & Personal Development
We work closely with our customers, fellow researcher and scientists to realize shared scientific and technical aspirations. We create a supportive environment to foster entrepreneurial spirit of our team members and collaborators.
We deliver a value-added product that overcomes impediments in everyday practice. We enable our product users to go further, to see beyond and overcome impediments that has not been possible before.